Effect of risedronate on biochemical marker of bone resorption in postmenopausal women with osteoporosis or osteopenia

References

• Srivastava A K, Vliet E L, Lewiecki E M, Maricic M, Abdelmalek A, Gluck O, Baylink D J. Clinical use of serum and urine bone markers in the management of osteoporosis. Curr Med Res Opin 2005; 21: 1015–1026
   PubMed Web of Science ®Google Scholar
• Rosen C J, Chesnut C H, Mallinak N J. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation. J Clin Endocrinol Metab 1997; 82: 1904–1910
   PubMed Web of Science ®Google Scholar
• Kanis J A, Delmas P, Burckhardt P, Cooper C, Torgerson D. Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease. Osteoporos Int 1997; 7: 390–406
   PubMed Web of Science ®Google Scholar
• Leung J Y, Ho A Y, Ip T P, Lee G, Kung A W. The efficacy and tolerability of risedronate on bone mineral density and bone turnover markers in osteoporotic Chinese women: a randomized placebo-controlled study. Bone 2005; 36: 358–364
   Google Scholar
• Raisz L, Smith J A, Trahiotis M, Fall P, Shoukri K, Digennaro J, Sacco-Gibson N. Short-term risedronate treatment in postmenopausal women: effects on biochemical markers of bone turnover. Osteoporos Int 2000; 11: 615–620
   PubMed Web of Science ®Google Scholar
• Ravn P, Thompson D E, Ross P D, Christiansen C. Biochemical markers for prediction of 4-year response in bone mass during bisphosphonate treatment for prevention of postmenopausal osteoporosis. Bone 2003; 33: 150–158
   PubMed Web of Science ®Google Scholar
• Christgau S, Bitsch-Jensen O, Hanover Bjarnason N, Gamwell Henriksen E, Qvist P, Alexandersen P, Bang Henriksen D. Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy. Bone 2000; 26: 505–511
   PubMed Web of Science ®Google Scholar
• Hannon R, Blumsohn A, Naylor K, Eastell R. Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability. J Bone Miner Res 1998; 13: 1124–1133
   PubMed Web of Science ®Google Scholar
• World Health Organization. Assessment of fracture risk and its application to screening for post-menopausal osteoporosis. Technical report series no. 843. World Health Organization, Geneva 1994; 1–129
   Google Scholar
• Branton R, Percival D A. Expressing biochemical markers of bone turnover as T-scores using Osteosal™, a rapid point of care test. J Bone Miner Res 1999; 14: S371
   Google Scholar
• Ilter E, Karalok H, Tufekci E C, Batur O. Efficacy and acceptability of risedronate 5 mg daily compared with 35 mg once weekly for the treatment of postmenopausal osteoporosis. Climacteric 2006; 9: 129–134
   PubMed Web of Science ®Google Scholar
• Bonde M, Qvist P, Fledelius C, Riis B J, Christiansen C. Applications of an enzyme immunoassay for a new marker of bone resorption (CrossLaps): follow-up on hormone replacement therapy and osteoporosis risk assessment. J Clin Endocrinol Metab 1995; 80: 864–868
   PubMed Web of Science ®Google Scholar
• Bjarnason N H, Christiansen C. Early response in biochemical markers predicts long-term response in bone mass during hormone replacement therapy in early postmenopausal women. Bone 2000; 26: 561–569
   PubMed Web of Science ®Google Scholar
• Gerdhem P, Ivaska K K, Alatalo S L, Halleen J M, Hellman J, Isaksson A, Pettersson K, Väänänen H K, Akesson K, Obrant K J. Biochemical markers of bone metabolism and prediction of fracture in elderly women. J Bone Miner Res 2004; 19: 386–393
   PubMed Web of Science ®Google Scholar
• Sarkar S, Reginster J Y, Crans G G, Diez-Perez A, Pinette K V, Delmas P D. Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. J Bone Miner Res 2004; 19: 394–401
   PubMed Web of Science ®Google Scholar
• Garnero P, Hausherr E, Chapuy M C, Marcelli C, Grandjean H, Muller C, Cormier C, Bréart G, Meunier P J, Delmas P D. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS prospective study. J Bone Miner Res 1996; 11: 1531–1538
   PubMed Web of Science ®Google Scholar
• Hochberg M C, Greenspan S, Wasnich R D, Miller P, Thompson D E, Ross P D. Changes in bone density and turnover explain the reductions in incidence of non-vertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 2002; 87: 1586–1592
   PubMed Web of Science ®Google Scholar
• Eastell R, Barton I, Hannon R A, Chines A, Garnero P, Delmas P. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003; 18: 1051–1056
   PubMed Web of Science ®Google Scholar
• Reginster J, Minne H W, Sorensen O H, Hooper M, Roux C, Brandi M L, Lund B, Ethgen D, Pack S, Roumagnac I, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000; 11: 83–91
   PubMed Web of Science ®Google Scholar
• Hannon R A, Branton R, Percival D A, Hibbert D L, Naylor K E, Machado A B, Eastell R. Comparison of measurement of urinary CrossLaps by Osteosal, a rapid point of care test and by ELISA. Bone 1998; 23: S630
   Google Scholar
• Percival D A, Chard M, Dawson C, Christrau S, Christiansen C. Measurement of urinary CrossLaps in patients treated with alendronate and Trisequens using the Osteosal rapid point of care test. Bone 1998; 23: S628
   Google Scholar
• Seibel M J. Biochemical markers of bone turnover, Part II: clinical applications in the management of osteoporosis. Clin Biochem Rev 2006; 27: 123–138
   PubMedGoogle Scholar
• Rosen H N, Moses A C, Garber J, Iloputaife I D, Ross D S, Lee S L, Greenspan S L. Serum CTx: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int 2000; 66: 100–103
   PubMed Web of Science ®Google Scholar
• Fall P M, Kennedy D, Smith J A, Seibel M J, Raisz L G. Comparison of serum and urine assays for biochemical markers of bone resorption in postmenopausal women with and without hormone replacement therapy and in men. Osteoporos Int 2000; 11: 481–485
   PubMed Web of Science ®Google Scholar
• Hosking D, Adami S, Felsenberg D, Andia J C, Välimäki M, Benhamou L, Reginster J Y, Yacik C, Rybak-Feglin A, Petruschke R A, et al. Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study. Curr Med Res Opin 2003; 19: 383–394
   PubMed Web of Science ®Google Scholar
• Braga de Castro-Machado A, Hannon R, Eastell R. Monitoring alendronate therapy for osteoporosis. J Bone Miner Res 1999; 14: 602–608
   Google Scholar